Aminoalcohol lipidoids and uses thereof

Patent metadata

Field	Value
Publication number	US-10844028-B2
Application number	US-201816208295-A
Country	US
Kind code	B2
Filing date	Dec 3, 2018
Priority date	Nov 7, 2008
Publication date	Nov 24, 2020
Grant date	Nov 24, 2020

Abstract

Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

First claim

What is claimed is:

1. A composition comprising a compound of formula:

wherein:
p is an integer between 1 and 3, inclusive;
m is an integer between 1 and 3, inclusive;
R A is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;

R F is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;

each occurrence of R 5 is independently substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;
wherein, at least one of R A , R F , R Y , and R Z is

each occurrence of x is an integer between 1 and 10, inclusive;
each occurrence of y is an integer between 1 and 10, inclusive;
each occurrence of R Y is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;

each occurrence of R Z is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;

or a pharmaceutically acceptable salt thereof; and an agent.

2. The composition of claim 1 , wherein R A is

3. The composition of claim 1 , wherein R F is

4. The composition of claim 1 , wherein R F is

5. The composition of claim 1 , wherein R A is

and
R F is

6. The composition of claim 1 , comprising a compound of the formula:

or a pharmaceutically acceptable salt thereof.

7. The composition of claim 1 , comprising a compound of the formula:

or a pharmaceutically acceptable salt thereof.

8. The composition of claim 1 , wherein the agent is selected from the group consisting of polynucleotides, proteins, peptides, and small molecule drugs.

9. The composition of claim 8 , wherein the agent is a polynucleotide.

10. The composition of claim 9 , wherein the polynucleotide is DNA.

11. The composition of claim 9 , wherein the polynucleotide is RNA.

12. The composition of claim 11 , wherein the RNA is antisense RNA, dsRNA, shRNA, or miRNA, wherein the RNA carries out RNA interference.

13. The composition of claim 9 , wherein the polynucleotide comprises regulatory regions to control the expression of a gene.

14. The composition of claim 9 , wherein the polynucleotide encodes a protein or peptide.

15. The composition of claim 9 , wherein the polynucleotide is used to fix an error in the genome of a cell being transfected.

16. The composition of claim 1 , wherein the composition is a particle.

17. The composition of claim 16 , wherein the particle further comprises PEG and cholesterol.

18. The composition of claim 16 , wherein the composition is a pharmaceutical composition.

19. A method of administering an agent, the method comprising administering to a subject in need thereof a therapeutically effective amount of a composition according to claim 1 .

20. The method of claim 19 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

21. The method of claim 20 , wherein agent is a polynucleotide.

22. The method of claim 21 , wherein the polynucleotide is DNA.

23. The method of claim 21 , wherein the polynucleotide is RNA.

24. The method of claim 23 , wherein the RNA is antisense RNA, dsRNA, shRNA, or miRNA, wherein the RNA carries out RNA interference.

25. The method of claim 21 , wherein the polynucleotide comprises regulatory regions to control the expression of a gene.

26. The method of claim 21 , wherein the polynucleotide encodes a protein or peptide.

27. The method of claim 21 , wherein the polynucleotide is used to fix an error in the genome of a cell being transfected.

28. The composition of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignees

• Massachusetts Inst Technology

Inventors

• Mahon Kerry Peter
• Love Kevin Thomas
• Levins Christopher G
• Whitehead Kathryn Ann
• Langer Robert S
• Anderson Daniel Griffith

Classifications

• C12N2320/32

  Special delivery means, e.g. tissue-specific · CPC title

• C12N2310/3515

  Lipophilic moiety, e.g. cholesterol · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• A61K48/0025

  wherein the non-active part clearly interacts with the delivered nucleic acid · CPC title

• B01J2531/845

  Cobalt · CPC title